Literature DB >> 19747472

Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?

Maniesh van der Vaart1, Pieter J Pretorius.   

Abstract

BACKGROUND: Circulating DNA is utilized widely as a genetic biomarker in a variety of pathological conditions, mainly in cancerous conditions. Quantification of circulating DNA and identifying the frequencies of a variety of mutations, microsatellite alterations and gene promoter methylation are the main foci of research on circulating DNA. CONTENT: A compilation of research reports available to us were reviewed to highlight the rather great variety of methods presently used to isolate circulating DNA, the lack of uniformity in presenting and interpreting quantitative research data as well as the virtual absence of information regarding the structure and function of circulating DNA.
CONCLUSIONS: The information compelled us to conclude that the application of circulating DNA as an unambiguous biomarker is currently overrated. We therefore emphasize the need for elucidating the prevailing questions regarding the origin, function and significance of these nucleic acid molecules before utilizing circulating DNA as a biomarker. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747472     DOI: 10.1016/j.clinbiochem.2009.08.027

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  27 in total

Review 1.  Nucleic acids in circulation: are they harmful to the host?

Authors:  Indraneel Mittra; Naveen Kumar Nair; Pradyumna Kumar Mishra
Journal:  J Biosci       Date:  2012-06       Impact factor: 1.826

2.  Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro.

Authors:  Janine Aucamp; Abel J Bronkhorst; Dimetrie L Peters; Hayley C Van Dyk; Francois H Van der Westhuizen; Piet J Pretorius
Journal:  Cell Mol Life Sci       Date:  2017-03-18       Impact factor: 9.261

Review 3.  Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.

Authors:  Mary Beth Terry; Jasmine A McDonald; Hui Chen Wu; Sybil Eng; Regina M Santella
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  Sensitive and direct electrochemical detection of double-stranded DNA utilizing alkaline phosphatase-labelled zinc finger proteins.

Authors:  Soodong Noh; Dat Thinh Ha; Haesik Yang; Moon-Soo Kim
Journal:  Analyst       Date:  2015-05-13       Impact factor: 4.616

5.  Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.

Authors:  Susan R Sturgeon; Raji Balasubramanian; Catherine Schairer; Hyman B Muss; Regina G Ziegler; Kathleen F Arcaro
Journal:  Epigenetics       Date:  2012-09-17       Impact factor: 4.528

6.  MGMT promoter methylation in plasma of glioma patients receiving temozolomide.

Authors:  Valentina Fiano; Morena Trevisan; Elisa Trevisan; Rebecca Senetta; Anna Castiglione; Carlotta Sacerdote; Anna Gillio-Tos; Laura De Marco; Chiara Grasso; Michela Magistrello; Fabrizio Tondat; Roberta Rudà; Paola Cassoni; Riccardo Soffietti; Franco Merletti
Journal:  J Neurooncol       Date:  2014-02-12       Impact factor: 4.130

7.  Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Authors:  Florent Mouliere; Safia El Messaoudi; Dalong Pang; Anatoly Dritschilo; Alain R Thierry
Journal:  Mol Oncol       Date:  2014-03-24       Impact factor: 6.603

8.  Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

Authors:  K Page; N Hava; B Ward; J Brown; D S Guttery; C Ruangpratheep; K Blighe; A Sharma; R A Walker; R C Coombes; J A Shaw
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

9.  Non-Invasive Detection of Esophageal Cancer using Genetic Changes in Circulating Cell-Free DNA.

Authors:  Saeid Ghorbian; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2012-01

10.  Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Authors:  Ellen Heitzer; Martina Auer; Eva Maria Hoffmann; Martin Pichler; Christin Gasch; Peter Ulz; Sigurd Lax; Julie Waldispuehl-Geigl; Oliver Mauermann; Sumitra Mohan; Gunda Pristauz; Carolin Lackner; Gerald Höfler; Florian Eisner; Edgar Petru; Heinz Sill; Hellmut Samonigg; Klaus Pantel; Sabine Riethdorf; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  Int J Cancer       Date:  2013-02-13       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.